<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086122</url>
  </required_header>
  <id_info>
    <org_study_id>Nº80-Separ2011</org_study_id>
    <nct_id>NCT03086122</nct_id>
  </id_info>
  <brief_title>The Impact of Obstructive Sleep Apnea in Erectile Dysfunction</brief_title>
  <official_title>The Impact of Obstructive Sleep Apnea in Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sociedad Española de Neumología y Cirugía Torácica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The syndrome of obstructive sleep apnea (OSA) is a common condition that affects 2-4% of the&#xD;
      general population, causing an increase in sympathetic activity, changes in systemic blood&#xD;
      pressure, and is associated with cardiovascular disease. The pathophysiological mechanisms&#xD;
      that are altered as a result of the events associated with obstructive sleep apnea&#xD;
      (hypoxia-reoxygenation, arousals and sleep fragmentation), are associated with an increased&#xD;
      risk of developing erectile dysfunction in patients with Obstructive Sleep Apnea. Until&#xD;
      today, the studies linking Erectile Dysfunction with Obstructive Sleep Apnea (OSA) are&#xD;
      epidemiological studies.&#xD;
&#xD;
      The alterations in the expression profile of endothelial and cardiovascular dysfunction&#xD;
      biomarkers and sex hormones disorders that are altered as a result of the events associated&#xD;
      with OSA are associated to erectile dysfunction development.&#xD;
&#xD;
      Treatment with continuous positive airway pressure (CPAP) reverses the effects of OSA and&#xD;
      patients with erectile dysfunction may improve erectile function.&#xD;
&#xD;
      The primary objective of the study is:&#xD;
&#xD;
      1. To evaluate the impact of CPAP treatment on erectile dysfunction in OSA patients.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        1. To determine the profile of synthesis of different biomarkers related to endothelial&#xD;
           dysfunction and cardiovascular disorder, which are altered as a result of the syndrome&#xD;
           of obstructive sleep apnea and its relation to the risk of developing erectile&#xD;
           dysfunction.&#xD;
&#xD;
        2. To compare the secretion profile of sex hormones related to control erectile function in&#xD;
           a group of patients with syndrome of obstructive sleep apnea with and without erectile&#xD;
           dysfunction.&#xD;
&#xD;
        3. To assess the prevalence of erectile dysfunction in patients with OSA.&#xD;
&#xD;
        4. To compare the psychological profile of patients with OSA with and without erectile&#xD;
           dysfunction in order to detect psychological distress associated with the risk of&#xD;
           developing erectile dysfunction.&#xD;
&#xD;
        5. To evaluate the impact of CPAP treatment on the secretion profile of sex hormones&#xD;
           related to control erectile function in OSA patients.&#xD;
&#xD;
        6. To evaluate the impact of CPAP treatment on the psychological profile of patients with&#xD;
           erectile disfunction in OSA patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in International Index Erectile Function (IIEF) score</measure>
    <time_frame>At baseline and 3 month</time_frame>
    <description>Effect of 3-months CPAP treatment on the changes in the International Index Erectile Function score of patients with Erectile Dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Self-Esteem And Relationship (SEAR) score</measure>
    <time_frame>At baseline and 3 month</time_frame>
    <description>Compare the psychological profile of patients with OSA with and without erectile dysfunction in order to detect psychological distress associated with the risk of developing erectile dysfunction, using SEAR score. Evaluate the impact of CPAP treatment on the change in SEAR score after 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Sexual hormone profile (Testosterone, SHBG, free Testosterone, Prolactin, LH, and FSH)</measure>
    <time_frame>At baseline and 3 month</time_frame>
    <description>Compare the secretion profile of sex hormones related to control erectile function in a group of patients with syndrome of obstructive sleep apnea with and without erectile dysfunction. Evaluate the impact of CPAP treatment on the change in the sexual hormone profile after 3 months. All hormones measured in blood samples by means of Radioimmunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Endothelial dysfunction biomarkers (ADMA, ICAM-1, VCAM-1, and VEGF)</measure>
    <time_frame>At baseline and 3 month</time_frame>
    <description>Determine the profile of synthesis of different biomarkers related to endothelial dysfunction and cardiovascular disorder associated to obstructive sleep apnea and its relation to the risk of developing erectile dysfunction. Evaluate the impact of CPAP treatment on the changes in endothelial dysfunction biomarkers after 3 months. All markers measured in blood samples by means of Radioimmunoassay.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Obstructive Sleep Apnea (OSA)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>OSA patients without erectile dysfunction (ED).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OSA + ED</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>OSA patients with erectile dysfunction diagnosis who are randomly allocated to not receive continuous positive airway pressure (CPAP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OSA + ED + CPAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSA patients with erectile dysfunction diagnosis who are randomly allocated to receive CPAP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous positive airway pressure</intervention_name>
    <description>Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.</description>
    <arm_group_label>OSA + ED + CPAP</arm_group_label>
    <other_name>CPAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of &quot;obstructive sleep apnea syndrome&quot; (Apnea-Hypopnea Index &gt;10)&#xD;
&#xD;
          -  Diagnosis of erectile dysfunction (International Index of Erectile Function score &lt;25)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psycho-physical inability to perform or collaborate with performing tests.&#xD;
&#xD;
          -  Patients presenting any of the following conditions:&#xD;
&#xD;
               -  cardiovascular diseases, neurological diseases (multiple sclerosis, Parkinson's&#xD;
                  disease, spinal disc disease).&#xD;
&#xD;
               -  history of pelvic or retroperitoneal surgery.&#xD;
&#xD;
               -  congenital or acquired malformations (Peyronie's disease, hypospadias,&#xD;
                  epispadias, penile fracture).&#xD;
&#xD;
               -  hormonal disorders (hypogonadism, hyperprolactinemia, hyper or hypothyroidism,&#xD;
                  Cushing's disease).&#xD;
&#xD;
               -  drug addiction and/or alcoholics and treatment with any of the following drugs:&#xD;
                  antidepressants, antipsychotics.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ferran Barbé, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spanish Respiratory Society</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova. IRB Lleida. CIBERes</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 12, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sociedad Española de Neumología y Cirugía Torácica</investigator_affiliation>
    <investigator_full_name>Ferran Barbe</investigator_full_name>
    <investigator_title>Head of Respiratory Medicine at Hospital Universitari Arnau de Vilanova</investigator_title>
  </responsible_party>
  <keyword>OSA</keyword>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>CPAP treatment</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>Cardiovascular risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

